Researchers discovered that the most common form of non-Hodgkin lymphoma is actually two distinct diseases
In 2000, researchers discovered that the most common form of non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma, is…
The Norris Foundation committed $15 million toward construction of the Harlyne J Norris Research Tower
On Jan. 10, 2012, the Norris Foundation made a $15 million commitment toward construction of the Harlyne J….
Stanford researchers first used gene expression profiling to distinguish cancer sub-types
In 2000, Stanford researchers led by Ash Alizadeh announced they had used gene expression profiling to identify two…
Georgetown Lombardi Comprehensive Cancer Center was founded
In 2000, Georgetown Lombardi Comprehensive Cancer Center, was founded when the Georgetown University Medical Center authorized the establishment…
The Jon M. Huntsman pledged $125 million to fund cancer research and construct the Huntsman Cancer Hospital
On Apr. 26, 2000, the Jon M. Huntsman pledged $125 million to fund cancer research and construct the…
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics
H. Jon Runstad and Judith M Runstad awarded E Donnall Thomas Medal of Achievement Medal
In 2000, the Fred Hutchinson Business Alliance announced that the E. Donnall Thomas Medal of Achievement was awarded…
Biotechnology | FDA | Oncology | Therapeutics
FDA approved Targretin to treat certain T-cell lymphomas
On Dec. 29, 1999, the U.S. Food and Drug Administration (FDA) approved Bexarotene (Targretin) to treat cutaneous T-cell…
The National Cancer Institute published Atlas of Cancer Mortality, 1950-94, showing geographic patterns of cancer death rates across U.S.
On Dec. 8, 1999, the National Cancer Institute published the Atlas of Cancer Mortality, 1950-94, showing the geographic…
Alvin and Ruth Siteman donated $35 to establish the Siteman Cancer Center
On Dec. 2, 1999, Alvin and Ruth Siteman donated $35 million to establish the Alvin J. Siteman Cancer…
National Colorectal Cancer Awareness Month was established
On Nov. 19, 1999, National Colorectal Cancer Awareness Month was established with a declaration by the U.S. Senate,…
NeoPath merged with AutoCyte to create TriPath Imaging
On Jun. 7, 1999, NeoPath merged with AutoCyte to form TriPath Imaging based in Burlington, N.C. NeoPath was…
The Study of Tamoxifen and Raloxifene began recruiting volunteers
On May 25, 1999. the Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer…
The Pancreatic Cancer Action Network was founded
On Feb. 8, 1999, The Pancreatic Cancer Action Network was founded by Paula Kim, Terry Lierman and Pamela…
The Carbone Cancer Center and McArdle Laboratories merged
In Jan. 1999, the Carbone Cancer Center and McArdle Laboratories merged and began to function as a single…
The Indiana University Cancer Center became an NCI-designated cancer center
In 1999, The Indiana University (IU) Cancer Center became an National Cancer Institute (NCI)-designated cancer center. Its mission…
The Hudson-Webber Cancer Research Center opened
In 1999, the Hudson-Webber Cancer Research Center opened to serve as a ‘translational’ research facility, bridging the gaps…
Timothy J Eberlein, MD was named director of the Alvin J Siteman Cancer Center
In 1999, Timothy J. Eberlein, MD was named director of the Alvin J. Siteman Cancer Center. As director…
Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer prevention
In 1999, Siteman Cancer Center investigators joined the STAR (Study of Tamoxifen and Raloxifene) trial for breast cancer…
Washington University – St Louis radiation oncologists helped develop the world’s first big bore CT scanner
In 1999, Washington University – St. Louis radiation oncologists were instrumental in developing the world’s first big bore…
Biotechnology | NIH | Oncology | Therapeutics
The Eppley Cancer Center became a National Cancer Institute designated cancer center
In 1999, the Eppley Cancer Center became a National Cancer Institute (NCI) designated cancer center. NCI grant funding…
The Prostate Centre at VGH received $20 million donation by Vancouver businessman Jim Pattison
In 1999, the Vancouver Prostate Centre received a $20 million donation by Vancouver businessman Jim Pattison, the largest…
Biotechnology | Diagnostics | NIH | Oncology | Therapeutics
UCSF Cancer Research Institute received NCI Comprehensive Cancer Center designation
In 1999, University of California at San Francisco Cancer Research Institute received NCI Comprehensive Cancer Center designation. The…
Samuel N. Stroum was awarded E. Donnall Thomas Medal of Achievement Medal
In 1999, the Fred Hutchinson Business Alliance announced that the 1999 E. Donnall Thomas Medal of Achievement would…
Trubion Pharmaceutical was founded
In 1999, Trubion Pharmaceutical was founded in Seattle as a spin-off from the Pacific Northwest Diabetes Research Institute,…
Mouse model of prostate cancer was developed at Washington University – St Louis
On Dec. 22, 1998, Washington University – St. Louis researcher Jeffrey I. Gordon, MD and colleagues developed a…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
Breast Cancer Prevention Trial Results published
On Sept. 14, 1998, researchers from the Breast Cancer Prevention Trial (BCPT) published a full report and update…
Biotechnology | Diagnostics | NIH | Non-Profit Research | Oncology | Therapeutics | U.S. Congress | Women's Health
The Stamp Out Breast Cancer stamp was first issued
On Jul. 29, 1998, the Stamp Out Breast Cancer stamp was first issued. The driving force behind the…
The Seattle Cancer Care Alliance was formed
On Jun. 16, 1998, University of Washington Medicine, Fred Hutchinson Cancer Research Center and Seattle Children’s announced the…
Biotechnology | FDA | Oncology | Therapeutics
The FDA approved Genentech drug Xeloda (capecitabine)
On April 30, 1998, the U.S. Food and Drug Administration (FDA) approved the Genentech’s drug Xeloda (capecitabine) for…